CVKD

Cadrenal Therapeutics, Inc. (CVKD) | Rumor.io

Cadrenal Therapeutics

CVKD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,418

Bullish sentiment (50-day avg)38%

Price to earnings ratio-0.17

Market capitalization3.5M

Earnings per share-4.88

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13.2M

Social

What share of all stock conversation is about CVKD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Sep 1

Cadrenal Therapeutics, Inc. (CVKD) has reached alignment with the FDA on the Phase 3 design for its CAD-1005 treatment in heparin-induced thrombocytopenia (HIT).
The FDA has agreed on the primary endpoint, protocol, and statistical analysis plan (SAP) for the Phase 3 trial.
Noble Capital Markets and Hc Wainright have issued reports and price targets for CVKD, with Noble Capital Markets stating that the Phase 3 design can move forward with expected endpoints.

Generated by AI

Sentiment

Of the messages about CVKD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	16.67% -70.83	84.69% -3.82
Bearish	—	—	83.33% +70.83	15.31% +3.82

Bullish· Feb 28

$CVKD's momentum is pointing toward higher levels, with a setup that's shaping up for continuation.
Buyers are defending higher levels nicely, showing patience and conviction as they step up with confidence.
The trend is shifting in favor of the bulls, with momentum gradually turning positive and volume picking up, indicating growing interest.

Bearish· Apr 9

$CVKD's price has dropped 25% with no apparent news, leading to confusion and frustration among investors.
The company's market capitalization has decreased significantly despite receiving good news, suggesting a disconnect between the asset's value and its fundamentals.
The high trading volume and price manipulation allegations suggest that market makers are actively working against the asset's price, potentially due to dilution or other negative factors.

Generated by AI

Topics

Of the messages about CVKD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	90%	67.01%
Technical Analysis	0%	0%	0%	9.15%
Analysts	0%	0%	10%	11.86%
Controversies	0%	0%	0%	0.13%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	11.86%

Announcements· Mar 18

Cadrenal Therapeutics, Inc. (CVKD) has been assigned price targets by analysts, with Noble Financial predicting $45, HC Wainwright at $32, and Zacks Small Cap Research at $25.
These price targets suggest potential upside of 250%-500% from the current share price of $7.64.
Research reports from Noble Financial, HC Wainwright, and Zacks Small Cap Research are available for review.

Technical Analysis· Feb 28

Momentum is pointing toward higher levels for $CVKD, with improving technical signals and bulls gaining traction.
Trendline support is working perfectly for $CVKD, with bulls maintaining steady pressure and preparing for the next leg up.
Multiple timeframes show strength for $CVKD, with momentum indicators leaning upward, chart pattern turning constructive, and price action looking increasingly bullish.

Generated by AI

Community

Of the messages about CVKD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	63.64%	29.17%	36.77%
Newcomers	100%	36.36%	70.83%	63.23%

Regulars· Mar 18

Analysts from Noble Financial, HC Wainwright, and Zacks Small Cap Research have set price targets for Cadrenal Therapeutics, Inc. Common Stock (CVKD) at $45, $32, and $25, respectively.
The current trading price of CVKD is $7.64 per share.
Analyst ratings suggest a potential upside of 250-500% from the current trading price.

Newcomers· Sep 1

Newcomers are focused on the FDA-related news and its impact on the stock's price, with some mentioning the potential for a new wave of movement.
The price target of $13 is being discussed, with some users mentioning it as a potential buy point.
The stock's price is being watched closely, with some users expecting a potential squeeze or a break through key levels, while others view it as "garbage" due to its past performance.

Generated by AI

PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in the 28th Annual H.C. Wainwright Global Investment Conference, September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company will be available on demand

26d agoYahoo Finance

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions,

29d agoYahoo Finance

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shieldingPONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and pr

1mo agoYahoo Finance

Cadrenal expands CAD-1005 development to two indications

1mo agoInvesting.com

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injuryDual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)Addresses High-Value Gap in the Acute Care Market –First-in-cl

1mo agoYahoo Finance

CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy

By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Moving Cadrenal to the Next Phase of its Evolution On July 21, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise while simultaneously initiating a structured partnering process for its late-stage

1mo agoYahoo Finance

Also Discussed

Investors talking about CVKD also mention

#	Name	Attention
1	NeoVolta Inc.NEOV	0%+0
2	Innovator Defined Wealth Shield ETFBALT	0%0
3	TruGolf Holdings, Inc. Class A Common StockTRUG	0%+0
4	Uni-Fuels Holdings Ltd.UFG	0%0
5	Esh Acquisition Corp.ESHA	0%0
6	Intelligent Bio Solutions Inc.INBS	0%0
7	AEye, Inc. Class A Common StockLIDR	0%0
8	TSBX - Turnstone Biologics Corp.	——
9	Tron Inc.SRM	0%0
10	Global X Dow 30 Covered Call ETFDJIA	0.06%+0.03

Cadrenal Therapeutics, Inc.

Healthcare
Biotechnology

Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing therapies for life-threatening immune and thrombotic conditions. Its lead program centers on CAD-1005, a first-in-class 12-LOX inhibitor being studied for heparin-induced thrombocytopenia, a serious immune-mediated clotting disorder. The company’s pipeline also includes tecarfarin, an oral vitamin K antagonist designed for patients with chronic anticoagulation needs, including those with end-stage kidney disease and left ventricular assist devices, as well as frunexian, a parenteral Factor XIa inhibitor being developed for acute hospital use. Cadrenal Therapeutics Inc. serves the specialized cardiovascular and hematology markets, where it aims to address unmet needs in anticoagulation and thrombosis management through targeted, clinically differentiated drug candidates.

Website

Location

822 A1A North

Ponte Vedra, FL, 32082

United States

Social

What share of all stock conversation is about CVKD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Sep 1

Cadrenal Therapeutics, Inc. (CVKD) has reached alignment with the FDA on the Phase 3 design for its CAD-1005 treatment in heparin-induced thrombocytopenia (HIT).
The FDA has agreed on the primary endpoint, protocol, and statistical analysis plan (SAP) for the Phase 3 trial.
Noble Capital Markets and Hc Wainright have issued reports and price targets for CVKD, with Noble Capital Markets stating that the Phase 3 design can move forward with expected endpoints.

Generated by AI

Sentiment

Of the messages about CVKD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	16.67% -70.83	84.69% -3.82
Bearish	—	—	83.33% +70.83	15.31% +3.82

Bullish· Feb 28

$CVKD's momentum is pointing toward higher levels, with a setup that's shaping up for continuation.
Buyers are defending higher levels nicely, showing patience and conviction as they step up with confidence.
The trend is shifting in favor of the bulls, with momentum gradually turning positive and volume picking up, indicating growing interest.

Bearish· Apr 9

$CVKD's price has dropped 25% with no apparent news, leading to confusion and frustration among investors.
The company's market capitalization has decreased significantly despite receiving good news, suggesting a disconnect between the asset's value and its fundamentals.
The high trading volume and price manipulation allegations suggest that market makers are actively working against the asset's price, potentially due to dilution or other negative factors.

Generated by AI

Topics

Of the messages about CVKD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	90%	67.01%
Technical Analysis	0%	0%	0%	9.15%
Analysts	0%	0%	10%	11.86%
Controversies	0%	0%	0%	0.13%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	11.86%

Announcements· Mar 18

Cadrenal Therapeutics, Inc. (CVKD) has been assigned price targets by analysts, with Noble Financial predicting $45, HC Wainwright at $32, and Zacks Small Cap Research at $25.
These price targets suggest potential upside of 250%-500% from the current share price of $7.64.
Research reports from Noble Financial, HC Wainwright, and Zacks Small Cap Research are available for review.

Technical Analysis· Feb 28

Momentum is pointing toward higher levels for $CVKD, with improving technical signals and bulls gaining traction.
Trendline support is working perfectly for $CVKD, with bulls maintaining steady pressure and preparing for the next leg up.
Multiple timeframes show strength for $CVKD, with momentum indicators leaning upward, chart pattern turning constructive, and price action looking increasingly bullish.

Generated by AI

Community

Of the messages about CVKD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	63.64%	29.17%	36.77%
Newcomers	100%	36.36%	70.83%	63.23%

Regulars· Mar 18

Analysts from Noble Financial, HC Wainwright, and Zacks Small Cap Research have set price targets for Cadrenal Therapeutics, Inc. Common Stock (CVKD) at $45, $32, and $25, respectively.
The current trading price of CVKD is $7.64 per share.
Analyst ratings suggest a potential upside of 250-500% from the current trading price.

Newcomers· Sep 1

Newcomers are focused on the FDA-related news and its impact on the stock's price, with some mentioning the potential for a new wave of movement.
The price target of $13 is being discussed, with some users mentioning it as a potential buy point.
The stock's price is being watched closely, with some users expecting a potential squeeze or a break through key levels, while others view it as "garbage" due to its past performance.

Generated by AI

Cadrenal Therapeutics

Social

Sep 1

Bullish· Feb 28

Bearish· Apr 9

Announcements· Mar 18

Technical Analysis· Feb 28

Regulars· Mar 18

Newcomers· Sep 1

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal expands CAD-1005 development to two indications

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy

Also Discussed

Cadrenal Therapeutics, Inc.

Company Information

Location

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal expands CAD-1005 development to two indications

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy

Also Discussed

Social

Sep 1

Bullish· Feb 28

Bearish· Apr 9

Announcements· Mar 18

Technical Analysis· Feb 28

Regulars· Mar 18

Newcomers· Sep 1